



Contra Costa Health Plan
P&T Formulary Update
December 23, 2019

Volume 12

Changes effective: 1/1/2020

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On December 5, 2019 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• Topical acne agents • Topical rosacea agents • Topical steroids • Conventional agents for psoriasis • Vitamins & minerals • Inhaled ICS/LAMA agents • Osteoporosis agents	• Allergenic Extracts • Blood glucose testing supplies • Conventional DMARD's • Hormone replacement therapy • Urinary tract antispasmodics • Eosinophilic asthma agents • Vaccines
Drug Monographs	
• None	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • Fasenra (benralizumab) • Nucala (mepolizumab) • Vascepa (icosapent ethyl) <u>Updates were made to the criteria for the following agents:</u> • Recombinant human growth hormone • Sensipar (cinacalcet) • Prolia (denosumab) • Forteo (teriparatide) • Reclast (zoledronic acid) • Otezla (apremilast) • Finacea (azelaic acid) • Vitamin D analogues (calcipotriene, calcitriol) • Accutane (isotretinoin) • Jakafi (ruxolitinib) <u>Criteria reviewed and unchanged:</u> • Allergenic extracts	

- Blood glucose testing supplies
- Conventional DMARD's
- Hormone replacement agents
- Urinary antispasmodic agents
- Vitamins & minerals
- DPP-4 inhibitors

The following drugs were added to the CCHP formulary:

- Malarone (atovaquone/proguanil)
- Advair Diskus (salmeterol/fluticasone)
- Boniva (ibandronate)
- Evisata (raloxifene)

Guest Speaker(s)

- None

CCHP P&T Committee approved the following modifications to the formulary:

Medication Name & Dosage Strength	Approved Formulary Changes
Malarone (atovaquone/proguanil)	Added to formulary, Tier 2 QL
Advair Diskus (salmeterol/fluticasone)	Added to formulary, Tier 1
Boniva (ibandronate)	Added to formulary, Tier 1
Evista (raloxifene)	Added to formulary, Tier 1

New Product Reviews (including new indications)

- | | |
|--|---|
| <ul style="list-style-type: none"> • Vyleesi (bremelanotide) • Turalio (pexidaritinib) • Corlanor (ivabridine) • Feriprox (deferiprone) • Varophen (diclofenac/salic/menthol) • LMR Plus (lido/menthol) • Quinixil (mometasone) • Rozlytrek (entrectinib) • Inrebic (fedratinib) • Cuvitru (IVIG) • Oraqix (lido/prilo) • Duaklir Pressair (aclidinium/formo) • Fiasp Penfill (insulin aspart) • Rybelsus (semaglutide) • Wakix (pitolisant) • Nourianz (istradefylline) • Ozobax (baclofen) • Drizalma Sprinkle (duloxetine) • PorAir Digihaler (albuterol) • Pedizol Pak (ketoconazole) • Tovet Kit (clobetasol) • Trikafta (elexacaftor/tezacaftor) | <ul style="list-style-type: none"> • Xenleta (lefamulin) • Rinvoq (upadacitinib) • NuCaraClinPak (clindamycin) • NuCaraRxPak (clindamycin/BP) • Clinolipid (phospholipids) • Vyndamax (tafamidis) • Myxredlin (regular insulin) • Inflastherm (diclofenac/menthol) • Nayzilam (midazolam) • Gvoke (glucagon) • Gvoke HypoPen (glucagon) • Tosymra (sumatriptan) • Kivik (palm oil/BP) • Relafen (nabumetone) • Asparlas (calaspargase) • Aklief (trifarotene) • Beovu (brolucizumab) • Harvoni (ledipasvir/sofosbuvir) • Sovaldi (sofosbuvir) • Xembify (IVIG) • Fasentra Pen (benralizumab) |
|--|---|